Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kestra Medical TechnologiesKMTS +4.90%12 Days Sales Outstanding is 43.42 as of Apr. 2026, which is 41% above its 10-year median of 30.75. GuruFocus rates KMTS with a GF Scoreâ„¢ of 12/100. The stock has 5 warning signs investors should review. Among 811 Medical Devices & Instruments companies, Kestra Medical Technologies ranks better than 82.86% on this metric.
The historical rank and industry rank for Kestra Medical Technologies's Days Sales Outstanding or its related term are showing as below:
KMTS'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 26.22 Med: 30.75 Max: 43.4
Current: 42.2
During the past 6 years, Kestra Medical Technologies's highest Days Sales Outstanding was 43.40. The lowest was 26.22. And the median was 30.75.
KMTS's Days Sales Outstanding is ranked better than 82.86% of 811
companies
in the Medical Devices & Instruments industry
Industry Median: 66.24
vs KMTS: 42.20
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kestra Medical Technologies Days Sales Outstanding Chart
KMTS vs AZTA, STAA, BLFS: Days Sales Outstanding Comparison
For the Medical Instruments & Supplies subindustry, Kestra Medical Technologies's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kestra Medical Technologies Days Sales Outstanding vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kestra Medical Technologies's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Kestra Medical Technologies's Days Sales Outstanding falls into.
Kestra Medical Technologies Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kestra Medical Technologies (KMTS) has a Days Sales Outstanding of 43.42 as of Apr. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Kestra Medical Technologies and its competitors. This is 41% above median its historical median of 30.75. Over the past decade, Kestra Medical Technologies' Days Sales Outstanding has ranged from 26.22 to 43.40. According to the industry distribution chart, Kestra Medical Technologies ranks #139 out of 811 companies in the Medical Devices & Instruments industry, placing it in the top 17.1%.
Is Kestra Medical Technologies' Days Sales Outstanding too high?
Kestra Medical Technologies' current Days Sales Outstanding of 43.42 is 41% above median its 10-year median of 30.75. Over the past 10 years, this metric has ranged from a low of 26.22 to a high of 43.40. The Medical Devices & Instruments industry median Days Sales Outstanding is 66.24. Kestra Medical Technologies' value of 43.42 is 34.5% below this industry median. Based on the distribution chart, Kestra Medical Technologies ranks #139 out of 811 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Kestra Medical Technologies has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Kestra Medical Technologies' Days Sales Outstanding compare to AZTA and STAA?
According to the Medical Devices & Instruments industry distribution chart, Kestra Medical Technologies ranks #139 out of 811 companies for Days Sales Outstanding. This places Kestra Medical Technologies in the top 17% of its industry — outperforming the majority of peers. The industry median Days Sales Outstanding is 66.24. Kestra Medical Technologies' value of 43.42 is 34.5% below this benchmark. Historically, Kestra Medical Technologies' own Days Sales Outstanding has ranged from 26.22 to 43.40 over the past decade. While the company's 10-year median is 30.75 vs. the industry median of 66.24, Kestra Medical Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Devices & Instruments company?
The median Days Sales Outstanding among Medical Devices & Instruments companies is 66.24, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kestra Medical Technologies's current Days Sales Outstanding of 43.42 is 34.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Kestra Medical Technologies and its competitors. For the Medical Devices & Instruments industry, the median Days Sales Outstanding is 66.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kestra Medical Technologies's current Days Sales Outstanding is 43.42, which is 41% above median its own 10-year median of 30.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kestra Medical Technologies stock overvalued right now?
Kestra Medical Technologies (KMTS) has a current Days Sales Outstanding of 43.42. The current Days Sales Outstanding is 43.42, which is 41% above median its 10-year median of 30.75 and 34.5% below the Medical Devices & Instruments industry median of 66.24. Kestra Medical Technologies' overall GF Score™ is 12/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Kestra Medical Technologies (KMTS), the current Days Sales Outstanding is 43.42 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kestra Medical Technologies Ltd is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. It has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and developed system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of its Cardiac Recovery System platform is the ASSURE WCD, a next-generation wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA), a prominent public health problem.
12GF Score
Get the complete analysis for KMTS
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KMTS has been successfully added to your 
